Advertisement

International Journal of Clinical Pharmacy

, Volume 41, Issue 5, pp 1247–1255 | Cite as

Multidisciplinary care in patients with systemic lupus erythematosus: a randomized controlled trial in China

  • Le Zhang
  • Shikai Geng
  • Liping Qian
  • Shuang Ye
  • Xiaodong Wang
  • Guohong Lu
  • Yang Ding
  • Ting LiEmail author
Research Article
  • 134 Downloads

Abstract

Background For the large number of systemic lupus erythematosus (SLE) patients in China, it is critical to carry out effective disease management to improve the treatment effect and reduce disease burden. A pharmacist-led multidisciplinary care model has not been reported in Chinese SLE patients before. Objective To assess the effect of patient-centered, pharmacist-led, multidisciplinary care on clinical outcomes and satisfaction with health care in Chinese SLE patients. Setting: The South Campus, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. Method Participants were 143 systemic lupus erythematosus patients randomly assigned to either the intervention group (multidisciplinary care: physician, pharmacist and nurse) or the control group (usual care only). Main outcome measures The primary outcome was scores on the systemic lupus erythematosus disease activity index-2000, the satisfaction with information about medicines scale, and the EuroQol five-dimension questionnaire, assessed at baseline and 12 months. Results Between October 1, 2017 and October 1, 2018, 42 participants were included in the intervention group and 40 in the control group. At 12 months, results for the systemic lupus erythematosus disease activity index-2000 differed significantly between the intervention group and the control group (0 vs. 2, P = 0.027). Patient satisfaction with health care was also significantly greater in the intervention group than in the control group (92.9 vs. 0%, P = 0.000). According to the EuroQol five-dimension questionnaire, health quality was also improved (0.94 vs. 0.85, P = 0.006). Conclusion Our multidisciplinary care team significantly improved clinical outcomes and satisfaction with drug information in Chinese systemic lupus erythematosus patients.

Keywords

China Patient-centered Pharmacist-led care Satisfaction with medicines information Systemic lupus erythematosus 

Notes

Funding

This study was funded by National Natural Science Foundation Youth Project (71804109), Shanghai Municipal Commission of Health and Family Planning scientific research project (20174Y0040), National Natural Science Foundation cultivation project of Renji Hospital (2017PYQA08), Cooperative Research Project of Innovation of Translational Medicine from Shanghai Jiaotong University (TM201807), and 2018 Pujiang Outstanding Youth Project of Renji Hospital South Campus (RJPJYQ2018).

Conflicts of interest

Le Zhang, Shikai Geng, Liping Qian, Shuang Ye, Xiaodong Wang, Guohong Lu, Yang Ding and Ting Li declare that they have no conflict of interest.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Data availability statements

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

  1. 1.
    Di Battista M, Marcucci E, Elefante E, Tripoli A, Governato G, Zucchi D, et al. One year in review 2018: systemic lupus erythematosus. Clin Exp Rheumatol. 2018;36(5):763–77.PubMedGoogle Scholar
  2. 2.
    Carter EE, Barr SG, Clarke AE. The global burden of SLE: prevalence, health disparities and socioeconomic impact. Nat Rev Rheumatol. 2016;12(10):605–20.CrossRefGoogle Scholar
  3. 3.
    Wang Z, Li M, Wang Y, Xu D, Wang Q, Zhang S, et al. Long-term mortality and morbidity of patients with systemic lupus erythematosus: a single-center cohort study in China. Lupus. 2018;27(5):864–9.CrossRefGoogle Scholar
  4. 4.
    de Larrinoa IR-FF. What is new in systemic lupus erythematosus. Reumatol Clin. 2015;11(1):27–32.CrossRefGoogle Scholar
  5. 5.
    Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487–97.CrossRefGoogle Scholar
  6. 6.
    Oliveira-Santos M. Erratum to: effectiveness of pharmaceutical care for drug treatment adherence in patients with systemic lupus erythematosus in Rio de Janeiro, Brazil: study protocol for a randomized controlled trial. Trials. 2017;18(1):96.CrossRefGoogle Scholar
  7. 7.
    Zhang L, Lu GH, Ye S, Wu B, Shen Y, Li T. Treatment adherence and disease burden of individuals with rheumatic diseases admitted as outpatients to a large rheumatology center in Shanghai, China. Patient Prefer Adherence. 2017;11:1591–601.CrossRefGoogle Scholar
  8. 8.
    Costedoat-Chalumeau N, Tamirou F, Piette JC. Treatment adherence in systemic lupus erythematosus and rheumatoid arthritis: time to focus on this important issue. Rheumatology (Oxford). 2018;57(9):1507–9.CrossRefGoogle Scholar
  9. 9.
    Williams EM, Lorig K, Glover S, Kamen D, Back S, Merchant A, et al. Intervention to improve quality of life for African-American lupus patients (IQAN): study protocol for a randomized controlled trial of a unique a la carte intervention approach to self-management of lupus in African Americans. BMC Health Serv Res. 2016;16(a):339.CrossRefGoogle Scholar
  10. 10.
    Choudhry NK, Isaac T, Lauffenburger JC, Gopalakrishnan C, Lee M, Vachon A, et al. Effect of a remotely delivered tailored multicomponent approach to enhance medication taking for patients with hyperlipidemia, hypertension, and diabetes: the STIC2IT cluster randomized clinical trial. JAMA Int Med. 2018;178(9):1182–9.CrossRefGoogle Scholar
  11. 11.
    Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI: a disease activity index for lupus patients: The committee on prognosis studies in SLE. Arthritis Rheum. 1992;35(6):630–40.CrossRefGoogle Scholar
  12. 12.
    Butler JA, Peveler RC, Roderick P, Horne R, Mason JC. Measuring compliance with drug regimens after renal transplantation: comparison of self-report and clinician rating with electronic monitoring. Transplantation. 2004;77(5):786–9.CrossRefGoogle Scholar
  13. 13.
    Liu GG, Wu H, Li M, Gao C, Luo N. Chinese time trade-off values for EQ-5D health states. Value Health. 2014;17(5):597–604.CrossRefGoogle Scholar
  14. 14.
    Jorgensen TS, Turesson C, Kapetanovic M, Englund M, Turkiewicz A, Christensen R, et al. EQ-5D utility, response and drug survival in rheumatoid arthritis patients on biologic monotherapy: a prospective observational study of patients registered in the south Swedish SSATG registry. PLoS One. 2017;12(2):e0169946.CrossRefGoogle Scholar
  15. 15.
    Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Fortin P, Ginzler E, et al. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. J Rheumatol. 2000;27(2):373–6.PubMedGoogle Scholar
  16. 16.
    Flynn A, Gilhooley E, O’Shea F, Wynne B. The use of SLICC and ACR criteria to correctly label patients with cutaneous lupus and systemic lupus erythematosus. Clin Rheumatol. 2018;37(3):817–8.CrossRefGoogle Scholar
  17. 17.
    Horne R, Hankins M, Jenkins R. The Satisfaction with Information about Medicines Scale (SIMS): a new measurement tool for audit and research. Qual Health Care. 2001;10(3):135–40.CrossRefGoogle Scholar
  18. 18.
    Boons C, Timmers L, van Schoor NM, Swart EL, Hendrikse NH, Janssen J, et al. Patient satisfaction with information on oral anticancer agent use. Cancer Med. 2018;7(1):219–28.CrossRefGoogle Scholar
  19. 19.
    Zhu GH, Wang YZ, Tong ZW. Reliability and validity of Chinese compliance questionnaire for rheumatology. Chin Gen Pract. 2013;16:2803–5.Google Scholar
  20. 20.
    van den Bemt BJ, van den Hoogen FH, Benraad B, Hekster YA, van Riel PL, van Lankveld W. Adherence rates and associations with nonadherence in patients with rheumatoid arthritis using disease modifying antirheumatic drugs. J Rheumatol. 2009;36(10):2164–70.CrossRefGoogle Scholar
  21. 21.
    Kumar K, Gordon C, Toescu V, Buckley CD, Horne R, Nightingale PG, et al. Beliefs about medicines in patients with rheumatoid arthritis and systemic lupus erythematosus: a comparison between patients of South Asian and White British origin. Rheumatology (Oxford). 2008;47(5):690–7.CrossRefGoogle Scholar
  22. 22.
    Menckeberg TT, Bouvy ML, Bracke M, Kaptein AA, Leufkens HG, Raaijmakers JA, et al. Beliefs about medicines predict refill adherence to inhaled corticosteroids. J Psychosom Res. 2008;64(1):47–54.CrossRefGoogle Scholar
  23. 23.
    Gabarron E, Dorronzoro E, Bradway M, Rivera-Romero O, Wynn R, Arsand E. Preferences and interests of diabetes social media users regarding a health-promotion intervention. Patient Prefer Adherence. 2018;12:2499–506.CrossRefGoogle Scholar
  24. 24.
    Morgado M, Rolo S, Castelo-Branco M. Pharmacist intervention program to enhance hypertension control: a randomised controlled trial. Int J Clin Pharm. 2011;33(1):132–40.CrossRefGoogle Scholar
  25. 25.
    Miller NH, Hill M, Kottke T, Ockene IS. The multilevel compliance challenge: recommendations for a call to action: a statement for healthcare professionals. Circulation. 1997;95(4):1085–90.CrossRefGoogle Scholar
  26. 26.
    Kesselheim AS, Misono AS, Shrank WH, Greene JA, Doherty M, Avorn J, et al. Variations in pill appearance of antiepileptic drugs and the risk of nonadherence. JAMA Intern Med. 2013;173(3):202–8.CrossRefGoogle Scholar
  27. 27.
    Chambers SA, Raine R, Rahman A, Isenberg D. Why do patients with systemic lupus erythematosus take or fail to take their prescribed medications? A qualitative study in a UK cohort. Rheumatology (Oxford). 2009;48(3):266–71.CrossRefGoogle Scholar
  28. 28.
    Feldman CH, Costenbader KH, Solomon DH, Subramanian SV, Kawachi I. Area-level predictors of medication nonadherence among U.S. medicaid beneficiaries with lupus: a multilevel study. Arthritis Care Res (Hoboken). 2018.  https://doi.org/10.1002/acr.23721.CrossRefPubMedCentralGoogle Scholar
  29. 29.
    Smith SM, Wallace E, O’Dowd T, Fortin M. Interventions for improving outcomes in patients with multimorbidity in primary care and community settings. Cochrane Database Syst Rev. 2016;3:Cd006560.PubMedGoogle Scholar
  30. 30.
    Salisbury C, Man MS, Bower P, Guthrie B, Chaplin K, Gaunt DM, et al. Management of multimorbidity using a patient-centred care model: a pragmatic cluster-randomised trial of the 3D approach. Lancet. 2018;392(10141):41–50.CrossRefGoogle Scholar
  31. 31.
    Peralta-Ramirez MI, Perez-Marmol JM, Castaneda-Cabestany M, Santos-Ruiz AM, Montero-Lopez E, Callejas-Rubio JL, et al. Association between perceived level of stress, clinical characteristics and psychopathological symptoms in women with systemic lupus erythematosus. Clin Exp Rheumatol. 2018;36(3):434–41.PubMedGoogle Scholar
  32. 32.
    Macedo EA, Appenzeller S, Costallat LTL. Depression in systemic lupus erythematosus: gender differences in the performance of the Beck Depression Inventory (BDI), Center for Epidemiologic Studies Depression Scale (CES-D), and Hospital Anxiety and Depression Scale (HADS). Lupus. 2018;27(2):179–89.CrossRefGoogle Scholar
  33. 33.
    Lee JW, Kang JH, Lee KE, Park DJ, Kang SW, Kwok SK, et al. Effects of risk factors for and components of metabolic syndrome on the quality of life of patients with systemic lupus erythematosus: a structural equation modeling approach. Qual Life Res. 2018;27(1):105–13.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Pharmacy, South Campus, Renji Hospital, School of MedicineShanghai Jiao Tong UniversityShanghaiChina
  2. 2.Department of Rheumatology, South Campus, Renji Hospital, School of MedicineShanghai Jiao Tong UniversityShanghaiChina
  3. 3.Department of Nursing, South Campus, Renji Hospital, School of MedicineShanghai Jiao Tong UniversityShanghaiChina
  4. 4.Department of Mathematics, Applied StatisticsShanghai Jiao Tong UniversityShanghaiChina

Personalised recommendations